Shares of Abbott Laboratories (NYSE:ABT) ended Thursday session in red amid volatile trading. The shares closed down -0.04 points or -0.10% at $41.85 with 7.69 million shares getting traded. Post opening the session at $42.12, the shares hit an intraday low of $41.65 and an intraday high of $42.12 and the price vacillated in this range throughout the day. The company has a market cap of $61.14 billion and the numbers of outstanding shares have been calculated to be 1.47 billion shares.
Abbott Laboratories (ABT) on Aug. 2, 2016 announced the introduction of Alinity™, its harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment.
Diagnostic testing guides 70 percent of health care decisions. Global testing volumes are rising due to an aging population, the growing management of chronic diseases and increased access to care. At the same time, health systems are facing pressures to perform testing as efficiently as possible with limited staff and space while also reducing costs. Many institutions and labs use multiple diagnostic platforms, often within a larger health care network. As they serve more patients and try to improve service levels with fewer qualified technicians, institutions are looking for new technologies that can help maximize testing efficiencies and help better manage resources.
Designed with universal, intuitive interfaces as well as common software and hardware, Abbott’s Alinity systems will have the ability to work together, providing greater capacity and simplifying the user experience. Several of the platforms will be designed to run more tests in less space, generate test results faster and minimize human errors. By offering a comprehensive solution that addresses the challenges of using multiple diagnostics platforms, while continuing to provide quality results that positively impact patient care, Alinity could potentially change the industry’s testing paradigm.
“Abbott’s Alinity portfolio is unprecedented in the industry,” said Brian Blaser, executive vice president, Diagnostics Products, Abbott. “With our unified family of testing instruments, we’ll be able to offer more efficiency, flexibility and confidence to health systems and better help doctors and nurses get the results they need to improve decision-making and patient care.”
Shares of Johnson & Johnson (NYSE:JNJ) ended Thursday session in red amid volatile trading. The shares closed down -0.14 points or -0.12% at $119.47 with 4.83 million shares getting traded. Post opening the session at $119.37, the shares hit an intraday low of $119.14 and an intraday high of $119.82 and the price vacillated in this range throughout the day. The company has a market cap of $326.47billion and the numbers of outstanding shares have been calculated to be 2.74 billion shares.
On Sept. 7, 2016 Johnson & Johnson is partnering with social action platform Global Citizen to help give every man, woman and child around the globe the opportunity for a healthier future. The partnership aims to create large-scale change for health systems through integrated solutions to help solve the world’s most pressing public health challenges.
“Good health is the cornerstone for a happy, fulfilling life,” said Lauren Moore, Johnson & Johnson Vice President of Corporate Citizenship. “Johnson & Johnson believes it is essential that we take a leading role in helping to build a future in which people everywhere have an equal opportunity to access quality healthcare, right from the very start. Through this partnership with Global Citizen, we hope to elevate awareness of the importance of strong public health programs and to also inspire others to join this global effort.”
The Johnson & Johnson-Global Citizen health campaign will focus on maternal and child health, particularly prenatal health care, child immunization targets and HIV and polio eradication. Through a combination of on-the-ground efforts, multimedia content and consumer activations, the campaign focuses on engaging people to take simple actions to support these causes. Starting and lasting for two weeks, citizens who want to create change can download the free Global Citizen app and participate in a range of actions for the opportunity to receive tickets to the Global Citizen Festival on September 24.
At this year’s “Global Citizen: The World on Stage” event on September 22, a documentary-style video following the lives of children living in the Nyumbani Village, a sustainable AIDS community in Nairobi, Kenya, will be spotlighted. The village was founded to support elders and children who are living with AIDS or orphaned due to AIDS, and has become a model of support for communities affected by the AIDS pandemic. Nyumbani supports some of the poorest populations affected by HIV/AIDS in sub-Saharan Africa and has eight centers that deliver comprehensive medical and home-based HIV/AIDS services in crucial areas of need. The stories of Nyumbani, delivered through films and onsite experiences, are meant to demonstrate the life-changing impact that can happen when people come together, and inspire more people to take action.